Compare ZVRA & ASPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVRA | ASPI |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.9M | 783.1M |
| IPO Year | 2015 | 2022 |
| Metric | ZVRA | ASPI |
|---|---|---|
| Price | $13.16 | $4.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $23.00 | $12.00 |
| AVG Volume (30 Days) | 1.5M | ★ 4.3M |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 159.21 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $106,470,000.00 | $23,849,000.00 |
| Revenue This Year | $37.27 | $68.41 |
| Revenue Next Year | $53.42 | $126.69 |
| P/E Ratio | $21.88 | ★ N/A |
| Revenue Growth | 350.91 | ★ 475.48 |
| 52 Week Low | $7.16 | $3.92 |
| 52 Week High | $15.04 | $14.49 |
| Indicator | ZVRA | ASPI |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 36.06 |
| Support Level | $8.26 | $3.98 |
| Resistance Level | $14.27 | $5.88 |
| Average True Range (ATR) | 0.67 | 0.53 |
| MACD | -0.17 | -0.18 |
| Stochastic Oscillator | 6.78 | 7.81 |
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.